PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3252768

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
ACTIVBIOTICS, INC. AND METAPHORE PHARMACEUTICALS, INC.	03/25/2008

RECEIVING PARTY DATA

Name:	KEREOS, INC.
Street Address:	4041 FOREST PARK AVENUE
City:	ST. LOUIS
State/Country:	MISSOURI
Postal Code:	63108
Name:	INOTEK PHARMACEUTICALS CORPORATION
Street Address:	131 HARTWELL AVENUE
City:	LEXINGTON
State/Country:	MASSACHUSETTS
Postal Code:	02421

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	13929222

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: patents.us@dentons.com, connie.payne@dentons.com
Correspondent Name: CONNIE PAYNE
Address Line 1: 233 SOUTH WACKER DRIV
Address Line 4: CHICAGO, ILLINOIS 60606

NAME OF SUBMITTER:	CONNIE PAYEN
SIGNATURE:	/Connie Payne/
DATE SIGNED:	03/05/2015

Total Attachments: 18
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page1.tif
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page2.tif

source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page3.tif
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page4.tif
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page5.tif
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page6.tif
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page7.tif
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page8.tif
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page9.tif
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page10.tif
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page11.tif
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page12.tif
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page13.tif
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page14.tif
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page15.tif
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page16.tif
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page17.tif
source=(ii) ActivBiotics and Metaphore to Kereos and Inotek Assignment executed March 2008#page18.tif

ASSIGNMENT OF PATENTS AND PATENT APPLICATIONS

This Assignment of Patents and Patent Applications ("Assignment"), effective as of March 26, 2008 (the "Effective Date"), is by and between Joseph F. Finn, Jr., as assignee for the benefit of creditors of ActivBiotics, Inc., a Delaware corporation (the "Company"), and Metaphore Pharmaceuticals, Inc., a Delaware corporation on the one hand (collectively, the "Sellers"), and Kereos, Inc., a Delaware corporation and Inotek Pharmaceuticals Corporation, a Delaware corporation on the other hand (collectively, the "Buyers").

WHEREAS, the Buyers and the Sellers are parties to that certain Bill of Sale and Sale Agreement, dated as of March 26, 2008 (the "Sale Agreement");

WHEREAS, pursuant to the Sale Agreement, the Sellers have agreed to execute and deliver this Assignment;

WHEREAS, the Sellers are the owner of the right, title and interest in and to certain patents (the "Owned Patents") and patent applications (the "Owned Patent Applications") and have certain interest in and to certain other patents (the "Pfizer Patents" and together with the owned Patents, the "Patents") and patent applications (the "Pfizer Patent Applications" and together with the Owned Patent Applications, the "Patent Applications") under that certain License Agreement by and between Pfizer Inc. and Metaphore Pharmaceuticals, Inc., dated December 19, 2003, as amended (the "Pfizer License Agreement"), the Owned Patents and Owned Patent Applications as specified in Exhibit A attached hereto and the Pfizer Patents and the Pfizer Patent Applications as specified in Exhibit B hereto, subject to any and all liens and encumbrances relating to such Patents and Patent Applications previously granted by the Company (but not subject to any liens and encumbrances held by any creditor assenting to the assignment for the benefit or creditors under which Joseph F. Finn, Jr. is acting on behalf of the Company);

WHEREAS, the Sellers are willing to assign to the Buyers their respective rights in such Patents and Patent Applications;

WHEREAS, the Buyers desire to obtain the Sellers' rights in the Patents and Patent Applications in accordance with the terms and conditions set forth in this Assignment and the Sale Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants and agreements hereinafter set forth, the sufficiency of which is acknowledged, the Buyers and the Sellers, intending to be legally bound, hereby agree as follows:

1. Assignment. The Sellers do hereby irrevocably grant, sell, convey, transfer, assign, deliver and relinquish exclusively to the Buyer, in perpetuity, all of their respective worldwide right, title, and interest in and to all of the Owned Patents and Owned Patent Applications, together with (i) any right to sue for and obtain remedies against past infringement and rights of priority and protection of interest in such Owned Patents and Owned Patent Applications that Sellers may have and (ii) any right to file and obtain any continuations, continuations-in-part, reissues, patent term extensions, divisionals and reexamination of the Owned Patents and Owned Patent Applications that Sellers may have, as applicable.

[redacted]

2. Recordation. In order to record this Assignment with the United States Patent and Trademark Office (the "PTO") in connection with the Owned Patents and the Owned Patent Applications, the parties hereto shall execute this Assignment and the Sellers shall execute the Recordation Cover Sheet required by the PTO in order to record the assignment effected hereby. Thereafter, the Sellers shall record the executed Recordation Form Cover Sheet with the PTO, together with any schedules and exhibits thereto, including, but not limited to, this Assignment and Exhibit A hereto.

3. Power of Attorney. The Sellers do hereby make, constitute and appoint the Buyers (and any officer or agent of the Buyers as the Buyers may select in their exclusive discretion) as the Sellers' true and lawful attorney-in-fact, with the power to endorse the Sellers' name on all applications, documents, papers and instruments necessary to implement and effect fully the intentions, purposes and provisions of this Assignment, including, but not limited to, the filing of any instrument of assignment and documents related thereto to effect such assignment of the Owned Patents and Owned Patent Applications in the PTO; provided, that the Buyer shall only be entitled to exercise its rights under this power of attorney with respect to any of the foregoing actions to the extent that the Sellers have failed to take such action at the request of the Buyers and following ten (10) days prior written notice to the Sellers of the exercise of such rights. This power of attorney shall be irrevocable.

4. Governing Law. This Assignment shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts and any suit or action hereunder, except as otherwise set forth herein, shall be brought in said jurisdiction.

5. Successors and Assigns. This Assignment shall bind the Sellers and their successors and assigns and inure to the benefit of Buyers and their successors and assigns.

[Signature page to follow]

[redacted]

This Assignment of Patents and Patent Applications is executed and delivered effective as of the date first set forth above.

ACTIVBIOTICS, INC.

By:_____
Joseph F. Finn, Jr., as and only as assignee for the benefit of creditors of ActivBiotics, Inc., and not individually.

METAPHORE PHARMACEUTICALS, INC.

By:_____
Steven C. Gilman
President

KEREOS, INC.

By:_____
Name:
Title:

[Address]

Telephone:
Fax:

INOTEK PHARMACEUTICALS CORPORATION

By:_____
Name:
Title:

[Address]

Telephone:
Fax:

[redacted]

COUNTY OF SUFFOLK :
: ss.:
COMMONWEALTH OF MASSACHUSETTS :

BE IT REMEMBERED, that on this 25TH day of March, 2008, before me, the subscriber, a notary public of the Commonwealth of Massachusetts, personally appeared Joseph F. Finn, Jr. who, I am satisfied, is the person who signed the foregoing Assignment of Patents and Patent Applications as the assignee for the benefit of creditors of ActivBiotics, Inc., a Seller named therein, and he thereupon acknowledged that the said instrument made by such Seller was signed, sealed with the corporate seal and delivered by him as such officer and is the voluntary act and deed of such Seller.

Andrea L. Travers
Notary Public

Andrea L. Travers
Notary Public
My Commission Expires
July 23, 2010

COUNTY OF SUFFOLK :
: ss.:
COMMONWEALTH OF MASSACHUSETTS :

BE IT REMEMBERED, that on this _____ day of March, 2008, before me, the subscriber, a notary public of the Commonwealth of Massachusetts, personally appeared Steven Gilman, who, I am satisfied, is the person who signed the foregoing Assignment of Patents and Patent Applications as the President and Chief Executive Officer of Metaphore Pharmaceuticals, Inc., a Seller named therein, and he thereupon acknowledged that the said instrument made by such Seller was signed, sealed with the corporate seal and delivered by him as such officer and is the voluntary act and deed of such Seller.

_____
Notary Public

[redacted]

This Assignment of Patents and Patent Applications is executed and delivered effective as of the date first set forth above.

ACTIVBIOTICS, INC.

By:_____
Joseph F. Finn, Jr., as and only as assignee for the benefit of creditors of ActivBioties, Inc., and not individually.

METAPHORE PHARMACEUTICALS, INC.

By:_____
Steven C. Gilman
President

KEREOS, INC.

By:_____
Name:
Title:

[Address]

Telephone:
Fax:

INOTEK PHARMACEUTICALS CORPORATION

By:_____
Name:
Title:

[Address]

Telephone:
Fax:

[redacted]

COUNTY OF SUFFOLK :
: ss.:
COMMONWEALTH OF MASSACHUSETTS :

BE IT REMEMBERED, that on this _____ day of March, 2008, before me, the subscriber, a notary public of the Commonwealth of Massachusetts, personally appeared Joseph F. Finn, Jr. who, I am satisfied, is the person who signed the foregoing Assignment of Patents and Patent Applications as the assignee for the benefit of creditors of ActivBiotics, Inc., a Seller named therein, and he thereupon acknowledged that the said instrument made by such Seller was signed, sealed with the corporate seal and delivered by him as such officer and is the voluntary act and deed of such Seller.

_____
Notary Public

COUNTY OF SUFFOLK :
: ss.:
COMMONWEALTH OF MASSACHUSETTS :

BE IT REMEMBERED, that on this 28th day of March, 2008, before me, the subscriber, a notary public of the Commonwealth of Massachusetts, personally appeared Steven Gilman, who, I am satisfied, is the person who signed the foregoing Assignment of Patents and Patent Applications as the President and Chief Executive Officer of Metaphore Pharmaceuticals, Inc., a Seller named therein, and he thereupon acknowledged that the said instrument made by such Seller was signed, sealed with the corporate seal and delivered by him as such officer and is the voluntary act and deed of such Seller.

_____
Notary Public

"Notary Public"
Jennifer K. Marten
Commonwealth of Massachusetts
My Commission Expires on Aug. 23, 2013

[redacted]

This Assignment of Patents and Patent Applications is executed and delivered effective as of the date first set forth above.

ACTIVBIOTICS, INC.

By: _____
Joseph F. Finn, Jr., as and only as assignee for the benefit of creditors of ActivBiotics, Inc., and not individually.

METAPHORE PHARMACEUTICALS, INC.

By: _____
Steven C. Gilman
President

KEREOS, INC.

By: _____
Name:
Title:

[Address]

Telephone:
Fax:

INOTEK PHARMACEUTICALS CORPORATION

By: _____
Name: MICHAEL LOBERG
Title: INTERIM PRESIDENT AND CEO

[Address] [redacted]

Telephone:
Fax:

[redacted]

This Assignment of Patents and Patent Applications is executed and delivered effective as of the date first set forth above.

ACTIVBIOTICS, INC.

By: _____
Joseph F. Finn, Jr., as and only as assignee for the benefit of creditors of ActivBiotics, Inc., and not individually.

METAPHORE PHARMACEUTICALS, INC.

By: _____
Steven C. Gilman
President

KEREOS, INC.

By: _____
Name: CATHERINE L. MATTHES
Title: CHIEF FINANCIAL OFFICER

[Addres[redacted]

Telepho
Fax:

INOTEK PHARMACEUTICALS CORPORATION

By: _____
Name:
Title:

[Address]

Telephone:
Fax:

[redacted]

Exhibit A to Assignment of Patents and Patent Applications

Sonnenschein Reference	Title	Serial No.	Filing Date	Subject Matter	Status	Coverage of M40403 and M40419
60019610-0355	COMPOSITIONS AND METHODS FOR ENHANCING CYTOKINE ACTIVITY AND TREATING HYPOTENSION ASSOCIATED WITH ADMINISTRATION OF CYTOKINE	10/433,290	12-16-2003	The present invention relates to compositions which enhance a mammal's immune response to a cytokine by administering therapeutic amounts of catalysts for the dismutation of superoxide which include superoxide dismutase enzyme (SOD) and small molecular weight organic ligand mimics of that enzyme (SOD mimetics or SODms), including M40403 in claims 70, 88, 97, and 108, alone or in combination with a cytokine. These compositions may be used in methods for enhancing a mammal's immune response to a virus such as the hepatitis C virus or the human immunodeficiency virus (HIV) or to a tumor thereby inhibiting the proliferation of the tumor. This invention also relates to methods of enhancing cancer therapy and methods of preventing and treating hypotension in a mammal resulting from the administration of cytokines by the administration of therapeutic amounts of catalysts for the dismutation of superoxide in combination with a cytokine and catecholamine pressor agents.	Pending; Final extension to Office Action due 2-7-2008 **Abandoned** **12/6/07: Pending abandonment."**	[redacted]
PATENTS ALSO ISSUED IN: N/A APPLICATIONS ALSO PENDING IN: Japan 2002-554093 and Europe 02707393.1						
60019610-0359	CHROMATOGRAPHY OF METAL COMPLEXES	10/469,440	1-29-2004	The present invention related to a high performance liquid chromatography method to routinely and reproducibly detect and quantitate metal complexes. The method comprises loading a solution containing metal complexes, which include M40403 in claims 15, 62, and 75, onto a column, eluting the metal complex from the column with a mobile phase, the mobile phase comprising an excess of a salt of a coordinating anion in a solvent system, and detecting the metal complex with a detector.	Pending; **Final Extension to Restriction Requirement due 6-4-2008**	Yes
PATENTS ALSO ISSUED IN: N/A APPLICATIONS ALSO PENDING IN: Japan 2002-569925, Canada 2439971, Europe 02721239.8						

Exhibit B to Assignment of Patents and Patent Applications

Sonnenschein Reference	Title	Serial No.	Filing Date	Subject Matter	Status	Coverage of M40403 and M40419
COMPOSITION OF MATTER						
60019610-0023	SUBSTITUTED PYRIDINO PENTAAZAMACROCYLE COMPLEXES HAVING SUPEROXIDE DISMUTASE ACTIVITY	09/398,120	9-16-1999	The present invention relates to compounds which are effective as catalysts for dismutating superoxide and, more particularly, the manganese or iron complexes of substituted, unsaturated heterocyclic pentaazacyclopentadecane ligands which catalytically dismutate superoxide. Broadly describes structure and function of substituted pyridino SODms, including derivatives of M40403 in claim 1. (Possible next-generation leads)	US 6,214,817 Issued 4-10-2001 **10/10/08 7.5 maintenance fee due**	[redacted]
PATENTS ALSO ISSUED IN: Australia 784078; Hong Kong HK1046689; Europe 1212323; United Kingdom 1212323; Italy 1212323; France 1212323; Germany 60011446.5; and Spain 2222[illegible] APPLICATIONS PENDING IN: Canada 2382105 and Japan 2001-523400						
60019610-0410	SUBSTITUTED PYRIDINO PENTAAZAMACROCYLE COMPLEXES HAVING SUPEROXIDE DISMUTASE ACTIVITY	EP 04003746.7	9-14-2000	The present invention relates to compounds which are effective as catalysts for dismutating superoxide, and more particularly, the manganese or iron complexes of substituted, unsaturated heterocyclic pentaazacyclopentadecane ligands which catalytically dismutase superoxide, including M40403 derivatives.	1420022 Issued 7-4-2007 **Nationalized National applications.**	
PATENTS ALSO ISSUED IN: United Kingdom 1420022; Germany 60035440.7; Italy 1420022; Spain 1420022; France 1420022; and Sweden 1420022 1212323; APPLICATIONS PENDING IN: N/A						

60019610-0411	SUBSTITUTED PYRIDINO PENTAAZAMACROCYLE COMPLEXES HAVING SUPEROXIDE DISMUTASE ACTIVITY	EP 04003751.7	9-14-2000	The present invention relates to compounds which are effective as catalysts for dismutating superoxide, and more particularly, the manganese or iron complexes of substituted, unsaturated heterocyclic pentaazacyclopentadecane ligands which catalytically dismutase superoxide, related to ligands only, and lincluding a ligand which, when chelated, would comprise M40403 derivative.	1420019 Issued 7-25-2007 **Nationalized** **National applications filed 9/27/07**	No
PATENTS ALSO ISSUED IN: United Kingdom 1420019; France 1420019; Italy 1420019; Sweden 1420019; Spain 1420019; and Germany 1420019 APPLICATIONS ALSO PENDING IN: N/A						
60019610-0031	MANGANESE COMPLEXES OF NITROGEN CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE	CA 2072934	7-2-1992	The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD), useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury. M40403 likely covered by claim 1, patent claims broadly to treatment of any disease caused by superoxide dismutase radicals	2072934 Issued 8-28-2007 **Annuity due 07/02/08**	[redacted]
60019610-0097	MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE	08/442,147	5-16-1995	The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD), useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury. Precursor ligand of M40403 not covered by claim 1, but patent limited to composition claims	US 6,084,093 Issued 7-4-2000 **11.5 Maintenance fee due 01/04/12**	[redacted]
60019610-0100	MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATNG SUPEROXIDE	08/469,064	6-6-1995	The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD), useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury. M40403 likely covered by claim 1, patent claims broadly to treatment of any disease caused by superoxide dismutase radicals.	US 5,874,421 Issued 2-23-1999 **11.5 Maintenance fee due 08/23/10**	Yes

60019610-0098	METHODS OF PREPARING MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS	08/442,455	5-16-1995	The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD), useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury. M40403 not covered by claim 1, but all claims to compositions or methods of making, no methods of treatment.	US 5,610,293 Issued 3-11-1997 **11.5 Maintenance fee 09/11/08**	No
60019610-0099	MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE	08/442,454	5-16-1995	The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD), useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury. M40403 likely covered by claim 1, which is to a pharmaceutical composition.	US 5,637,578 Issued 6-10-1997 **11.5 Maintenance fee 12/10/08**	Yes
60019610-0195	MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE	NZ 272364	7-13-1992	The present invention relates to compounds effective as catalysts for dismutating superoxide and, more particularly, related to manganese(II) or manganese(III) complexes of nitrogen-containing fifteen-membered macrocyclic ligands which catalytically dismutate superoxide. Precursor ligand of M40403 not covered by claim, but all claims to compositions or methods of making, no methods of treatment.	NZ 272364 Issued 6-17-1996 **Patent Expiration 07/13/12**	[redacted]s
60019610-0048	MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE	KR 700147/1994	7-2-1992	The present invention relates to compounds effective as catalysts for dismutating superoxide and, more particularly, related to manganese(II) or manganese(III) complexes of nitrogen-containing fifteen-membered macrocyclic ligands which catalytically dismutate superoxide. Precursor ligand of M40403 not covered by claim 1, but all claims to compositions or methods of making, no methods of treatment.	KR 145953 Issued 7-9-1998 **Annuity due 05/06/08**	Yes

PATENTS ALSO ISSUED IN: Europe 0598753 ; Japan 3155552; Australia 661023; Germany 69224839.0; Spain 92915849.1; France 0598753; United Kingdom 0598753; Italy 0598753; and South Korea 154346
APPLICATIONS PENDING IN: N/A

60019610-0056	MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE	08/004,444	1-14-1993	The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD), useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, myocardial infarction, stroke, atherosclerosis, and all other conditions of oxidant-induced tissue damage or injury. M40403 likely covered in claim 1.	US 6,204,259 Issued 3-20-2001 **7.5 Maintenance due 09/20/08**	Yes
PATENTS ALSO ISSUED IN: N/A APPLICATIONS PENDING IN: N/A						
60019610-0090	MANGANESE OR IRON COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE	08/596,887	3-14-1996	Low molecular weight mimics of superoxide dismutase (SOD), useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, and all other conditions of oxidant-induced tissue damage or injury. Broad claims to pharmaceutically active compositions; M40403 likely covered in claim 1.	U.S. 6,525,041 Issued 2-25-2003 **7.5 Maintenance due 08/25/10**	[redacted]
PATENTS ALSO ISSUED IN: N/A APPLICATION PENDING IN: Canada 2224060						
60019610-0499	POLYETHYLENE GLYCOLATED SUPEROXIDE DISMUTASE MIMETICS	11/766221	7-21-2007	Compounds and methods for utilizing compounds comprising a superoxide dismutase mimetic covalently linked to polyethylene glycol. Methods are also provided for preparing a superoxide dismutase mimetic covalently linked to a polyethylene glycol, the methods comprising reacting an activated polyethylene glycol with a superoxide dismutase mimetic, or alternatively, reacting a superoxide dismutase mimetic with an activated polyethylene glycol. A method is also provided for preventing or treating a disease or disorder in which superoxide anions are implicated, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound comprising a superoxide dismutase mimetic covalently linked to a polyethylene glycol. Methods of determining the safety and efficacy of the compounds are also provided. Methods for determining the safety and efficacy can include methods in lab animals and humans. M40403 in application for broad treatment, coupled to PEG.	Pending; Awaiting Action **Pending** **Information Disclosure Statement due**	Yes

PATENTS ALSO ISSUED IN: N/A
APPLICATION PENDING IN: Canada 2591970

METHODS OF USE--TREATING ORAL MUCOSITIS

60019610-0513	METHODS OF TREATING ORAL MUCOSITIS	11/871848	10/12/2007	Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation. Claims 21 and 49 are directed to method of treatment using M40403 and a kit using M40403, respectively.	Pending; **First Extension to Missing Parts due 4-3-2008**	No
60019610-0514	METHODS OF TREATING ORAL MUCOSITIS	PCT/US07/21897	10/12/2007	Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation. Claims 21 and 49 are directed to method of treatment using M40403 and a kit using M40403, respectively.	Pending: **Response to correct defects due 2-14-2008**	[redacted]

COMBINATION THERAPY

60019610-0386	COMBINATION THERAPY OF AN SODM AND A CORTICOSTERIOD FOR PREVENTION AND/OR TREATMENT OF INFLAMMATORY DISEASE	10/481,396	6-2-2004	The present invention relates to pharmaceutical compositions and methods using such compositions for the treatment of inflammatory disease. Such compositions contain a catalyst for the dismutation of superoxide, including superoxide dismutase enzyme (SOD) and low molecular weight organic ligand derived metal complexes that function as mimics of the enzyme (SOD mimetics or SODm) in combination with corticosteroids. M40403 likely part of broad claims to SOD mimetics, but patent limited to inflammation and it's treament.	Pending; **Awaiting Action**	No

PATENTS ISSUED IN: N/A
APPLICATIONS ALSO PENDING IN: Europe 02752107.9; Japan 2003-507099; Canada 2451602 and Mexico PA/a/2003/011795

60019610-0483	COMBINATION THERAPY OF SODm AND CORTICOSTEROID FOR PREVENTION AND/OR TREATMENT OF INFLAMMATORY BONE OR JOINT DISEASE	11/141,550	5-31-2005	The present invention relates to pharmaceutical compositions and methods of using such compositions for the treatment of inflammatory diseases of the bone and joints. The compositions comprise a catalyst for the dismutation of superoxide, which is a non-proteinaceous mimetic of superoxide dismutase, in combination with a corticosteroid. The combination is substantially more effective than either the superoxide dismutase mimetic or the corticosteroid given alone at the same dose. Treatment with the combination beneficially alters the progression of the inflammatory bone and joint disease as measured histologically in diminished bone resorption and infiltration of inflammatory cells; as measured radiographically in diminished joint erosion, and diminished bone erosion and osteophyte formation; and as measured histomorphometrically in decreased bone resorption measurements of eroded surface and/or osteoclast surface relative to bone surface, and increased bone formation measurements of osteoblast surface relative to bone surface. Claims 15, 33, 51, 67, 81, and 96 cover M40403 as compound used in method of treatment.	Restriction Requirement **4th extension due 5-19-2008**	No
PATENTS ISSUED IN: N/A APPLICATIONS ALSO PENDING IN: N/A						
METHODS OF MANUFACTURING AND PROCESS						
60019610-0120	ANALGESIC METHODS USING SYNTHETIC CATALYSTS FOR THE DISMUTATION OF SUPEROXIDE RADICALS	09/057,831	4-9-1998	The present invention relates to synthetic low molecular weight catalysts for the dismutation of superoxide, which are potent analgesics that are effective in elevating the pain threshold in hyperalgesic conditions such as arthritis, and also operate to prevent or reverse tolerance to opioid analgesics. Describes structure and function of SODms, including M40403 in example 157. M40403 likely covered in broad claim 1.	US 6,180,620 Issued 1-30-2001 **7.5 Maintenance Fee due 07/30/08**	No
PATENTS ALSO ISSUED IN: Australia 733415; Europe 1001752; Germany 69820633.9; Spain 1001752; France 1001752; United Kingdom 1001752; and Italy 1001752 APPLICATIONS PENDING IN: Japan 504593/1999						

60019610-0219	BIOMATERIALS MODIFIED WITH SUPEROXIDE DISMUTASE MIMICS	EP 00932810.5	5-26-2000	The present invention relates to biomaterials modified with non-proteinaceous catalysts for the dismutation of superoxide, and processes for making such materials. This modification may be by covalent conjugation, copolymerization, or admixture of the non-proteinaceous catalyst with the biomaterial. The resulting modified biomaterials exhibit a marked decrease in inflammatory response and subsequent degradation when placed in contact with vertebrate biological systems. M40403 covered in claim 1.	EP 1185312 National	Yes
PATENTS ALSO IN: Germany 60018925.2; Spain 1185312; Italy 1185312; France 1185312; and United Kingdom 1185312 APPLICATIONS PENDING IN: U.S. 09/580,007 and Japan 2000-620999						
60019610-0469	BIOMATERIALS MODIFIED WITH SUPEROXIDE DISMUTASE MIMETICS	EP 05006278.5	5-26-2000	The present invention relates to biomaterials modified with non-proteinaceous catalysts for the dismutation of superoxide, and processes for making such materials. This modification may be by covalent conjugation, copolymerization, or admixture of the non-proteinaceous catalyst with the biomaterial. The resulting modified biomaterials exhibit a marked decrease in inflammatory response and subsequent degradation when placed in contact with vertebrate biological systems. M40403 covered in claim 1 and Table 1.	Pending; Awaiting Action **Nationals due 04/09/08**	[redacted]es
60019610-0232	ANALGESIC METHODS USING SYNTHETIC CATALYSTS FOR THE DISMUTATION OF SUPEROXIDE RADICALS	09/634,152	8-9-2000	The present invention is directed to synthetic low molecular weight catalysts for the dismutation of superoxide, which are potent analgesics that are effective in elevating the pain threshold in hyperalgesic conditions such as arthritis, and also operate to prevent or reverse tolerance to opioid analgesics. Describes structure and function of SODms, including M40403 in example 157. M40403 likely covered in claim 4.	US 6,395,725 Issued 5-28-2002 **7.5 Maintenance fee due 11/28/09**	[redacted]lo
60019610-0461	SODm THERAPY FOR TREATMENT, PREVENTION, INHIBITION AND REVERSAL OF INFLAMMATORY DISEASE	10/971,799	10-21-2004	The present invention relates to the use of a manganese complex of a heterocyclic pentaazacyclopentadecane ligand, including M40403 in example 157 and claims 3 and 8, which is effective as a catalyst for dismutating superoxide, particularly in treating, preventing, inhibiting and reversing inflammatory disease.	Pending; **Awaiting Action**	Yes.

PATENTS ISSUED IN: N/A
APPLICATIONS ALSO PENDING IN: N/A

METHODS OF USE--DIAGNOSTIC, IMAGING AND DETECTION

60019610-0154	METHODS OF DIAGNOSTIC IMAGE ANALYSIS USING METAL COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS	08/698,612	8-16-1996	The present invention is directed to metal complexes of nitrogen containing macrocyclic ligands for use as contrast agents in diagnostic imaging. Method claims that broadly cover metal complexes of nitrogen containing macrocyclic ligands; likely that M40403 is covered in claim 1.	US 5,976,498 Issued 11-2-1999 **11.5 Maintenance Fee due 05/02/11**	No
60019610-0351	METHODS OF DIAGNOSTIC IMAGE ANALYSIS USING BIOCONJUGATES OF METAL COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS	10/737,486	12-16-2003	The present invention is directed to bioconjugates of complexes for use as contrast agents in diagnostic imaging. Claimed complexes of the invention include M40403.	Pending; **Petition to Revive filed 12-4-2007**	[redacted]es

PATENTS ALSO ISSUED IN: N/A
APPLICATIONS ALSO PENDING IN: N/A

KITS

60019610-0500	METHOTREXATE COMBINATIONS FOR TREATING INFLAMMATORY DISEASES	11/814347	7-19-2007	The present invention relates to compounds, methods and kits for treating inflammatory diseases. The treatment comprises administering to a patient in need thereof, methotrexate and a Reactive Oxygen Species scavenger, including M40403 in claims 15 and 41, in a pharmaceutically acceptable formulation.	Pending; **Awaiting Action**	Yes

A/72506810.1

PATENTS ALSO ISSUED IN: N/A
APPLICATIONS ALSO PENDING IN: PCT/US06/01733

[redacted]